Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma

被引:14
作者
Bron, LP
Scolyer, RA
Thompson, JF
Hersey, P
机构
[1] Newcastle Mater Hosp, Immunol & Oncol Unit, Newcastle, NSW 2300, Australia
[2] Royal Prince Alfred Hosp, Sydney Head & Neck Canc Inst, Sydney, NSW, Australia
[3] Royal Prince Alfred Hosp, Dept Anat Pathol, Sydney, NSW, Australia
[4] Royal Prince Alfred Hosp, Sydney Melanoma Unit, Sydney, NSW, Australia
[5] Royal Prince Alfred Hosp, Melanoma & Skin Canc Res Inst, Sydney, NSW, Australia
[6] Univ Sydney, Discipline Surg, Fac Med, Sydney, NSW 2006, Australia
关键词
tumour necrosis factor-related apoptosis-inducing ligand; tumor necrosis factor-related apoptosis-inducing ligand; TRAIL; cutaneous melanoma; apoptosis; pathology;
D O I
10.1080/00313020400011268
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aims: Tumour necrosis factor-related apoptosis ligand (TRAIL) appears to selectively induce apoptosis in a wide range of cultured malignant cells, including melanoma. This study was designed to attempt to clarify the role of TRAIL in the biology of human melanoma. Methods: Tissue sections cut from formalin-fixed, paraffin-embedded tissue blocks of 45 primary cutaneous melanomas were tested for expression of TRAIL using immunohistochemistry. The intensity, pattern of staining and percentage of positively stained tumour cells were evaluated in each melanoma. Breslow thickness, ulcerative state, dermal mitotic rate and the presence of tumour infiltrating lymphocytes were measured/determined in each case. Median follow up for the cohort of patients was 10 months (range 1-18). Survival analysis was conducted using the Kaplan-Meier method. The level of expression of TRAIL was compared with the various histological determinants using the two-tailed Fisher's exact test and the chi(2)-test. Results: Overall and disease-free survival were 72 and 48%, respectively, and did not correlate with TRAIL expression. Among the pathological prognostic determinants, only mitotic rate showed a statistically significant correlation with TRAIL expression using the chi(2)-test (P=0.04). Conclusion: We conclude that TRAIL expression in melanoma defines a more aggressive/proliferative phenotype, either through selection of apoptotic resistant cells or by secondary induction of other factors enhancing proliferation of more malignant cells. Analysis of a larger group of patients with longer follow-up is required to determine whether TRAIL expression correlates with survival of patients.
引用
收藏
页码:561 / 565
页数:5
相关论文
共 33 条
[1]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[2]   Targeting death and decoy receptors of the tumour-necrosis factor superfamily [J].
Ashkenazi, A .
NATURE REVIEWS CANCER, 2002, 2 (06) :420-430
[3]   Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma - An analysis of 3661 patients from a single center [J].
Azzola, MF ;
Shaw, HM ;
Thompson, JF ;
Soong, SJ ;
Scolyer, RA ;
Watson, GF ;
Colman, MH ;
Zhang, YT .
CANCER, 2003, 97 (06) :1488-1498
[4]   Disruption of NF-κB signaling reveals a novel role for NF-κB in the regulation of TNF-related apoptosis-inducing ligand expression [J].
Baetu, TM ;
Kwon, H ;
Sharma, S ;
Grandvaux, N ;
Hiscott, J .
JOURNAL OF IMMUNOLOGY, 2001, 167 (06) :3164-3173
[5]  
Dhawan P, 2002, CANCER RES, V62, P7335
[6]   TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB [J].
Ehrhardt, H ;
Fulda, S ;
Schmid, I ;
Hiscott, J ;
Debatin, KM ;
Jeremias, I .
ONCOGENE, 2003, 22 (25) :3842-3852
[7]   Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) [J].
Fanger, NA ;
Maliszewski, CR ;
Schooley, K ;
Griffith, TS .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (08) :1155-1164
[8]  
Giovarelli M, 1999, J IMMUNOL, V163, P4886
[9]  
Gliniak B, 1999, CANCER RES, V59, P6153
[10]   Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors [J].
Gratas, C ;
Tohma, Y ;
Van Meir, EG ;
Klein, M ;
Tenan, M ;
Ishii, N ;
Tachibana, O ;
Kleihues, P ;
Ohgaki, H .
BRAIN PATHOLOGY, 1997, 7 (03) :863-869